计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
S413720-2mg |
2mg |
现货 ![]() |
| |
S413720-5mg |
5mg |
期货 ![]() |
| |
S413720-10mg |
10mg |
现货 ![]() |
| |
S413720-50mg |
50mg |
现货 ![]() |
| |
S413720-100mg |
100mg |
期货 ![]() |
|
英文别名 | 3-Azetidinecarboxylic acid, 1-[[4-[(1E)-1-[[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]- | (Z)-4-Cyano-5-((3,5-dichloropyridin-4-yl)thio)-N-(4-(methylsulfonyl)phenyl)thiophene-2-carbimidic acid | BAF-312(SiponiMod) | |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | Siponimod (BAF312) |
生化机理 | BAF312 (Siponimod) 是新一代 S1P 受体激动剂,对 S1P1 和 S1P5 受体具有选择性,EC50 为 0.39 nM 和 0.98 nM,对 S1P2、S1P3 和 S1P4 受体的选择性大于 1000 倍。第 3 阶段 |
储存温度 | -20°C储存,充氩 |
运输条件 | 超低温冰袋运输 |
作用类型 | 激动剂 |
作用机制 | 1- 磷酸鞘氨醇受体 Edg-1 激动剂 |
产品介绍 |
Information Siponimod (BAF312) BAF312 (Siponimod) is a next-generation S1P receptor agonist, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3. Targets S1P1 receptor ; S1P5 receptor 0.39 nM(EC50); 0.98 nM(EC50) In vitro BAF312 (Siponimod) is a potent and selective S1P receptor agonist, with EC50 of 0.39 nM and 0.98 nM for S1P1 and S1P5receptors, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. BAF312 (1 h at 1 μM) promotes prominent internalization of S1P1 receptors by 91%. In vivo BAF312 effectively suppresses encephalomyelitis (EAE) in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes. BAF312 significantly reduces clinical scores when dosed prophylactically or therapeutically in mice at 0.3 mg/kg. Cell Research(from reference) Cell lines:CHO Concentrations:~1 μM Incubation Time:1 h |
ALogP | 3.834 |
---|---|
Rotatable Bond | 10 |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
分子类型 | 小分子 |
---|---|
IUPAC Name | 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid |
INCHI | InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+ |
InChi Key | KIHYPELVXPAIDH-HNSNBQBZSA-N |
Canonical SMILES | CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O |
Isomeric SMILES | CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O |
PubChem CID | 44599207 |
分子量 | 516.6 |
溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (193.57 mM); Ethanol: 44 mg/mL warmed with 50ºC Water: bath (85.17 mM); Water: Insoluble; |
---|---|
敏感性 | 易吸潮 |
DMSO(mg / mL) Max Solubility | 100 |
DMSO(mM) Max Solubility | 193.5733643 |
Water(mg / mL) Max Solubility | <1 |
熔点 | 154 - 157°C |
分子量 | 516.600 g/mol |
XLogP3 | 4.800 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 8 |
可旋转键计数Rotatable Bond Count | 9 |
精确质量Exact Mass | 516.26 Da |
单同位素质量Monoisotopic Mass | 516.26 Da |
拓扑极表面积Topological Polar Surface Area | 62.100 Ų |
重原子数Heavy Atom Count | 37 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 777.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 1 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
1. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG et al.. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.. Br J Pharmacol, 167 (5): (1035-47). [PMID:22646698] [10.1021/op500134e] |
2. Lewis ND, Haxhinasto SA, Anderson SM, Stefanopoulos DE, Fogal SE, Adusumalli P, Desai SN, Patnaude LA, Lukas SM, Ryan KR et al.. (2013) Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.. J Immunol, 190 (7): (3533-40). [PMID:23436932] [10.1021/op500134e] |
3. O'Sullivan C, Schubart A, Mir AK, Dev KK. (2016) The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.. J Neuroinflammation, 13 (13): (31). [PMID:26856814] [10.1021/op500134e] |
4. Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, Tuntland T, Che J, Lefebvre S, Chen Y et al.. (2013) Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.. ACS Med Chem Lett, 4 (3): (333-7). [PMID:24900670] [10.1021/op500134e] |
5. Subei AM, Cohen JA. (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis.. CNS Drugs, 29 (7): (565-75). [PMID:26239599] [10.1021/op500134e] |
6. Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L et al.. (2016) Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.. J Neuroinflammation, 13 (1): (207). [PMID:27566665] [10.1021/op500134e] |
7. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T et al.. (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.. Lancet, 391 (10127): (1263-1273). [PMID:29576505] [10.1021/op500134e] |